Equillium to Participate in Upcoming Investor Conferences

LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences:

Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.

Investors and the general public are invited to listen to a live webcast of the presentation on the Events & Presentations page, located under the Investor Relations section on equilliumbio.com. An archived replay of both presentations will be available for 90 days.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways. 

For more information, visit www.equilliumbio.com.

Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
[email protected]

You May Also Be Interested In

• SPIRIT BLOCKCHAIN CAPITAL REPORTS SECOND QUARTER 2026 RESULTS & PROVIDES CORPORATE UPDATE
• Inventus Selects SRK Consulting to Complete Maiden Mineral Resource Estimate at Pardo
• General Oncology Nominated for the 2026 Prix Galien USA Best Startup Award